ATE413386T1 - Ppar-gamma modulatoren - Google Patents

Ppar-gamma modulatoren

Info

Publication number
ATE413386T1
ATE413386T1 AT99901492T AT99901492T ATE413386T1 AT E413386 T1 ATE413386 T1 AT E413386T1 AT 99901492 T AT99901492 T AT 99901492T AT 99901492 T AT99901492 T AT 99901492T AT E413386 T1 ATE413386 T1 AT E413386T1
Authority
AT
Austria
Prior art keywords
ppar
gamma modulators
modulators
gamma
obesity
Prior art date
Application number
AT99901492T
Other languages
English (en)
Inventor
La Brouse-Elwood Fabienne De
Juan Jaen
Lawrence Mcgee
Shi-Chang Miao
Steven Rubenstein
Jin-Long Chen
Timothy Cushing
John Flygare
Jonathan Houze
Patrick Kearney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE413386T1 publication Critical patent/ATE413386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Measurement Of Radiation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT99901492T 1998-01-29 1999-01-20 Ppar-gamma modulatoren ATE413386T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7304298P 1998-01-29 1998-01-29

Publications (1)

Publication Number Publication Date
ATE413386T1 true ATE413386T1 (de) 2008-11-15

Family

ID=22111361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99901492T ATE413386T1 (de) 1998-01-29 1999-01-20 Ppar-gamma modulatoren

Country Status (9)

Country Link
US (3) US6200995B1 (de)
EP (1) EP1053227B1 (de)
JP (1) JP4253126B2 (de)
AT (1) ATE413386T1 (de)
AU (1) AU759255B2 (de)
CA (1) CA2318731C (de)
DE (1) DE69939864D1 (de)
ES (1) ES2317688T3 (de)
WO (1) WO1999038845A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038845A1 (en) * 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
ES2437103T3 (es) * 1999-06-30 2014-01-08 Amgen Inc. Compuestos para la modulacion de la actividad de PPAR gamma
CA2407587A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited Ppar.gamma. modulators
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
IL153461A0 (en) * 2000-06-28 2003-07-06 Tularik Inc Quinolinyl and benzothiazolyl derivatives and pharmaceutical compositions containing the same
CA2415189A1 (en) * 2000-07-31 2002-02-07 University Of Maryland, Baltimore Immunomodulatory compounds
CA2425259A1 (en) * 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US20040198979A1 (en) * 2001-05-07 2004-10-07 Dashyant Dhanak Sulfonamides
AR033879A1 (es) 2001-05-07 2004-01-07 Smithkline Beecham Corp Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
EP1385841A4 (de) * 2001-05-07 2005-03-02 Smithkline Beecham Corp Sulfonamide
BR0209558A (pt) * 2001-05-11 2004-04-20 Biovitrum Ab Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0212512A (pt) 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
CA2784937A1 (en) * 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7420055B2 (en) * 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
CA2500492C (en) 2002-11-18 2010-03-16 Solomon Ungashe Aryl sulfonamides
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DE602004010889T2 (de) * 2003-02-14 2008-12-11 Eli Lilly And Co., Indianapolis Sulfonamid-derivate als ppar-modulatoren
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
BRPI0412380A (pt) 2003-07-08 2006-09-19 Novartis Ag compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
EP1718625A1 (de) * 2004-02-18 2006-11-08 AstraZeneca AB Verbindungen
EP2048137A1 (de) * 2004-02-18 2009-04-15 AstraZeneca AB Benzamid Derivate und ihre Verwendung als Glucokinase auslösenden Wirkstoffe
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
US7262318B2 (en) 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
EP2712617B2 (de) 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Behandlung Von Fibrose Mit Fxr-Liganden
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005272786B2 (en) 2004-08-12 2011-12-22 Amgen Inc. Bisaryl-sulfonamides
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
SE0402635D0 (sv) * 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
ES2397648T3 (es) * 2005-07-09 2013-03-08 Astrazeneca Ab Derivados de heteroarilbenzamida para uso como activadores de GLK en el tratamiento de la diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
TW200833339A (en) * 2006-12-21 2008-08-16 Astrazeneca Ab Novel crystalline compound
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
US8410083B2 (en) 2007-01-19 2013-04-02 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
US20100080786A1 (en) 2008-05-20 2010-04-01 Markus Berger Phenyl or Pyridinyl Substituted Indazoles Derivatives
CN102164940B (zh) 2008-07-30 2015-08-19 英特塞普特医药品公司 Tgr5调节剂及其使用方法
CA2732165A1 (en) * 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
KR101667436B1 (ko) 2008-11-19 2016-10-18 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ５ 조절제 및 그의 사용 방법
DK2379507T3 (da) * 2008-12-30 2014-01-27 Pulmagen Therapeutics Inflammation Ltd Sulfonamidforbindelser til behandling af åndedrætsforstyrrelser
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
NZ600926A (en) * 2010-01-04 2013-07-26 Nippon Soda Co Nitrogen-containing heterocyclic compound and agricultural/horticultural germicide
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
JP6084926B2 (ja) 2010-09-21 2017-02-22 インテクリン・セラピユーテイクス・インコーポレイテツド 抗糖尿病固体医薬組成物
EP2624695B1 (de) 2010-10-08 2015-09-23 Nivalis Therapeutics, Inc. Neue substituierte chinolinverbindungen als s-nitrosoglutathion-reduktasehemmer
BR112013014681A2 (pt) 2010-12-16 2016-10-04 N30 Pharmaceuticals Inc novos compostos aromáticos bicíclicos substituídos como inibidores de s-nitrosoglutationa redutase
MX344238B (es) * 2011-01-26 2016-12-07 Zafgen Inc Compuestos de tetrazol y métodos para preparar y usar los mismos.
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
ES2797123T3 (es) 2011-12-21 2020-12-01 Novira Therapeutics Inc Agentes antivirales para la hepatitis B
EA201990211A1 (ru) 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN104902885A (zh) 2012-08-28 2015-09-09 爱尔兰詹森科学公司 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
PL2961732T3 (pl) 2013-02-28 2017-09-29 Janssen Sciences Ireland Uc Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP3357906B1 (de) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamidesubstituierte pyrrolamidderivate und verwendung davon als medikamente zur behandlung von hepatitis b
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
HK1225389A1 (zh) 2014-02-06 2017-09-08 Janssen Sciences Ireland Uc 氨磺酰基吡咯酰胺衍生物及其作为药物用於治疗乙型肝炎的用途
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
EP3356328A1 (de) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Kristalline formen eines hepatitis-b-viruzids
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
JP2022516509A (ja) 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
US20220193102A1 (en) 2019-04-02 2022-06-23 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3946334A1 (de) 2019-04-04 2022-02-09 Coherus Biosciences, Inc. Zusammensetzungen und verfahren zur behandlung von nichtalkoholischen fettleberkrankheiten (nafld)
US20220288054A1 (en) 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205025A1 (en) 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3946337A1 (de) 2019-04-04 2022-02-09 Coherus Biosciences, Inc. Zusammensetzungen und verfahren zur behandlung von nichtalkoholischen fettleberkrankheiten (nafld)
EP3966205A1 (de) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company In der behandlung einer hbv-infektion oder von hbv-induzierten erkrankungen nützliche amidderivate
EP3976037A1 (de) 2019-05-30 2022-04-06 Coherus Biosciences, Inc. Zusammensetzungen und verfahren zur behandlung von krebs
WO2021076616A1 (en) 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
WO2022051323A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
WO2022051318A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
WO2022051319A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
CN113912669A (zh) * 2021-06-28 2022-01-11 北京大学深圳研究生院 基于环构象的抗菌化合物设计、合成及应用
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407309A (en) 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
CH361275A (de) 1957-09-10 1962-04-15 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
US3033870A (en) * 1958-03-24 1962-05-08 Ciba Pharm Prod Inc Certain derivatives of 4-(aminophenylmercapto)-pyridine
US3700773A (en) 1969-06-25 1972-10-24 Merck & Co Inc Substituted phenylsulfamyl salicyclic acids and derivatives thereof in the treatment of inflammation
US3686192A (en) 1971-01-04 1972-08-22 Minnesota Mining & Mfg Substituted pyridine derivatives
US4061642A (en) 1972-06-22 1977-12-06 Cassella Farbwerke Mainkur Ag 2,4,6-Trisubstituted-3-pyridine carboxamides
US4003734A (en) 1974-01-22 1977-01-18 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl-acetamides, -ureas and urea derivatives and herbicidal compositions and methods containing said compounds
CH592411A5 (en) * 1974-04-18 1977-10-31 Ciba Geigy Ag Phenoxymethyl- and phenylthiomethyl-pyridine derivs - with insecticidal, acaricidal and plant-growth regulating activity
US4013621A (en) 1975-04-29 1977-03-22 Ciba-Geigy Corporation Substituted sulfonamide derivatives of hindered phenols and stabilized compositions
GB2009146B (en) 1977-11-29 1982-03-24 Ishihara Sangyo Kaisha Sulphonanilide copmouds and herbicidal compositions therof
NZ191078A (en) * 1978-08-08 1982-05-31 Ici Australia Ltd Bis(pyrimidyloxy) benzenes bis(pyrimidylthio)benzenes and prymidyloxy-pyrimidyl thiobenzens and herbicidal compositions
US4289876A (en) 1978-11-24 1981-09-15 Bristol-Myers Company Antisecretory agents
JPS5579369A (en) 1978-12-13 1980-06-14 Ishihara Sangyo Kaisha Ltd Urea compound, its preparation, and insecticide comprising it
US4499304A (en) 1981-07-06 1985-02-12 Eastman Kodak Company Color-forming sulfonamidodiphenylamines and corresponding sulfonimide dyes
DE3264551D1 (en) 1981-07-06 1985-08-08 Eastman Kodak Co Color-forming sulfonamidodiphenylamines, photographic elements containing them and corresponding sulfonimide dyes
EP0078234B1 (de) 1981-10-20 1990-07-04 Ciba-Geigy Ag 5-Halogenalkyl-pyridine
US4565568A (en) 1982-06-18 1986-01-21 The Dow Chemical Company Pyridyl(oxy/thio)phenoxy compounds, herbicidal compositions and methods
US4731090A (en) 1983-12-23 1988-03-15 Ciba-Geigy Corporation Process for protecting keratinous material from attack by insects feed on keratin with pyridyloxytrifluoromethanesulfonanilides
US4549901A (en) 1984-02-16 1985-10-29 Stauffer Chemical Company 2-[4-(Substituted aryl)phenoxy]-N-substituted-phenylsulfonyl propionamides having herbicidal properties
US4851419A (en) * 1985-10-16 1989-07-25 Fisons Plc Certain 2-pyridinyl-phenylsulfinyl-benzoxazoles, the corresponding benzothiazoles or benzimidazoles having anti-inflammatory or gastric acid secretion inhibition activity
US4651419A (en) * 1985-11-08 1987-03-24 Reed Jr August D Double ended single blade knife
DE3545570A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate und deren n-oxide, verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte
US4866079A (en) 1986-03-19 1989-09-12 Ciba-Geigy Corporation N-pyridyloxyphenylisothioureas and the use thereof in pest control
US5202336A (en) * 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
FI882394A7 (fi) * 1986-09-27 1988-05-20 Fisons Plc Yhdisteet.
JPS646245A (en) 1987-02-20 1989-01-10 Sumitomo Chemical Co Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient
US4670045A (en) 1987-04-07 1987-06-02 The Dow Chemical Company Fungicidal control employing ester derivatives of 4,6-disubstituted 2-pyridinols
GB8724252D0 (en) 1987-10-15 1987-11-18 Ici Plc Fungicides
JPS646245U (de) 1987-06-30 1989-01-13
JPH01156953A (ja) * 1987-09-01 1989-06-20 Hokko Chem Ind Co Ltd ベンゼンスルホンアニリド誘導体および農園芸用殺菌剤
DE3852621D1 (de) 1987-12-07 1995-02-09 Ciba Geigy Ag 3-Aminobenzoylphenylharnstoffe.
DE3823318A1 (de) 1988-07-09 1990-02-22 Bayer Ag (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
GB8820115D0 (en) 1988-08-24 1988-09-28 Ici Plc Insecticidal compounds
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
ZA913760B (en) 1990-05-24 1992-02-26 Sumitomo Chemical Co Pyridine derivatives,their production processes and their compounds for control of insect pests
GB9015658D0 (en) 1990-07-17 1990-09-05 Shell Int Research Herbicidal compounds
DE69129611T2 (de) 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
JP3188286B2 (ja) 1991-08-20 2001-07-16 塩野義製薬株式会社 フェニルメトキシイミノ化合物およびそれを用いる農業用殺菌剤
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
US5643914A (en) 1993-03-02 1997-07-01 Smithkline Beecham Corporation Pharmaceutical pyridine compounds
HUT73813A (en) * 1993-06-30 1996-09-30 Wellcome Found Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
WO1995033462A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
US5684195A (en) 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (de) 1994-11-12 1997-12-01 Zeneca Ltd
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US5814646A (en) * 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0778267A4 (de) * 1995-06-21 2000-04-05 Otsuka Kagaku Kk Sulfonamid-derivate enthaltende insektizide, mitizide und nematizide
WO1997010813A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
ES2205183T3 (es) 1996-02-22 2004-05-01 Tularik, Inc. Pentafluorobencenosulfonamidas y analogos.
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09255656A (ja) 1996-03-28 1997-09-30 Hiroyoshi Hidaka スルフォンアミド誘導体及びこれを含有する医薬
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
JP3243733B2 (ja) 1996-08-07 2002-01-07 雪印乳業株式会社 新規イソキノリン誘導体
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
ES2189142T3 (es) * 1997-02-21 2003-07-01 Bayer Ag Arilsulfonamidas y sus analogos y su uso en el tratamiento de enfermedades neurodegenerativas.
EP0869122B1 (de) * 1997-03-31 2002-12-04 Korea Research Institute Of Chemical Technology Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
AU7371998A (en) 1997-05-07 1998-11-27 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
CA2295239A1 (en) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
JP2002512997A (ja) 1998-04-29 2002-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｍｐｄｈ酵素のインヒビター
HN1998000027A (es) * 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE19837627A1 (de) * 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
HUP0200355A3 (en) 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US6202336B1 (en) * 1999-05-24 2001-03-20 Allan E. Audino Safety device for firearms
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
WO2001030343A1 (en) 1999-10-22 2001-05-03 Merck & Co., Inc. Pharmaceuticals for treating obesity
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
KR20030064852A (ko) 2000-12-22 2003-08-02 이시하라 산교 가부시끼가이샤 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제

Also Published As

Publication number Publication date
US6200995B1 (en) 2001-03-13
US7439242B2 (en) 2008-10-21
EP1053227A1 (de) 2000-11-22
WO1999038845A1 (en) 1999-08-05
AU759255B2 (en) 2003-04-10
ES2317688T3 (es) 2009-04-16
US20030088103A1 (en) 2003-05-08
JP4253126B2 (ja) 2009-04-08
DE69939864D1 (de) 2008-12-18
AU2117699A (en) 1999-08-16
US6620827B2 (en) 2003-09-16
EP1053227B1 (de) 2008-11-05
JP2002501945A (ja) 2002-01-22
CA2318731C (en) 2012-05-29
US20010027200A1 (en) 2001-10-04
CA2318731A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
ATE413386T1 (de) Ppar-gamma modulatoren
NZ516455A (en) Compounds for the modulation of PPARgamma activity
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO20061736L (no) Krystallform av epotilon B
IL151313A0 (en) Lipase containing pharmaceutical compositions
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE69905170T2 (de) Thiazolopyrimidinderivate
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
ATE305517T1 (de) Neurotrypsin
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
PT1092040E (pt) Metodos de inibicao helicobacter pylori
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties